• Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq • Investment focus on entrepreneurial innovation in therapeutics in Europe • Total assets under management >€220 million ($250m) NAARDEN, The Netherlands, June 24, 2020-- BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund’s original target. The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, Schroder Adveq and the European Investment Fund.